Terms: = Colorectal cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
183 results:
1. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the clinical significance of IL-38 correlation with PD-1, ctla-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
He R; Huang S; Lu J; Su L; Gao X; Chi H
Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and immunological role of adaptor related protein complex 3 subunit mu2 in colon cancer.
Jin Q; Feng J; Yan Y; Kuang Y
Sci Rep; 2024 Jan; 14(1):483. PubMed ID: 38177168
[TBL] [Abstract] [Full Text] [Related]
6. 68Ga-FAPI PET imaging monitors response to combined TGF-βR inhibition and immunotherapy in metastatic colorectal cancer.
Li K; Liu W; Yu H; Chen J; Tang W; Wang J; Qi M; Sun Y; Xu X; Zhang J; Li X; Guo W; Li X; Song S; Tang S
J Clin Invest; 2024 Jan; 134(4):. PubMed ID: 38175716
[TBL] [Abstract] [Full Text] [Related]
7. [Inflammatory bowel diseases: Transformation of representations. A review].
Maev IV; Bakulin IG; Skalinskaya MI; Skazyvaeva EV
Ter Arkh; 2023 Dec; 95(12):1064-1074. PubMed ID: 38158940
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical Expression of Immune Checkpoints; ctla-4, LAG3, and TIM-3 in cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract] [Full Text] [Related]
9. Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients.
Hajebi Khaniki S; Shokoohi F; Esmaily H; Kerachian MA
Sci Rep; 2023 Dec; 13(1):22104. PubMed ID: 38092774
[TBL] [Abstract] [Full Text] [Related]
10. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
11. GPX3 is a key cholesterol-related gene associated with prognosis and tumor-infiltrating T cells in colorectal cancer.
Chen J; Wu Y; Zhou Q; Song Y; Zhuang J; Lu K; Yang X
Neoplasma; 2023 Oct; 70(5):. PubMed ID: 38053382
[TBL] [Abstract] [Full Text] [Related]
12. Metastases and treatment-resistant lineages in patient-derived cancer cells of colorectal cancer.
Fujino S; Miyoshi N; Ito A; Hayashi R; Yasui M; Matsuda C; Ohue M; Horie M; Yachida S; Koseki J; Shimamura T; Hata T; Ogino T; Takahashi H; Uemura M; Mizushima T; Doki Y; Eguchi H
Commun Biol; 2023 Nov; 6(1):1191. PubMed ID: 37996567
[TBL] [Abstract] [Full Text] [Related]
13. A pan-cancer analysis of the MAPK family gene and their association with prognosis, tumor microenvironment, and therapeutic targets.
Qin YY; Yang Y; Ren YH; Gao F; Wang MJ; Li G; Liu YX; Fan L
Medicine (Baltimore); 2023 Nov; 102(45):e35829. PubMed ID: 37960824
[TBL] [Abstract] [Full Text] [Related]
14. The Potential Dual Role of H2.0-like Homeobox in the Tumorgenesis and Development of colorectal cancer and Its Prognostic Value.
Chen S; Zhang L; Wang K; Huo J; Zhang S; Zhang X
Can J Gastroenterol Hepatol; 2023; 2023():5521544. PubMed ID: 37719132
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.
Ji J; Liu S; Liang Y; Zheng G
BMC Genom Data; 2023 Aug; 24(1):44. PubMed ID: 37568073
[TBL] [Abstract] [Full Text] [Related]
16. Expression of Immune-Related and Inflammatory Markers and Their Prognostic Impact in colorectal cancer Patients.
An S; Kim SK; Kwon HY; Kim CS; Bang HJ; Do H; Kim B; Kim K; Kim Y
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511338
[TBL] [Abstract] [Full Text] [Related]
17. Noncoding RNAs-based high KIF26B expression correlates with poor prognosis and tumor immune infiltration in colon cancer.
Liu Z; Zhou X; Chen B; Wu Z; Zhang C; Gu C; Li J; Yang X
Cell Cycle; 2023; 22(14-16):1726-1742. PubMed ID: 37436127
[TBL] [Abstract] [Full Text] [Related]
18. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients.
Liu J; Dou M; Liu X; Lu Y; Lu W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11995-12012. PubMed ID: 37421455
[TBL] [Abstract] [Full Text] [Related]
19. Assessment of essential and toxic elemental concentrations in tumor and non-tumor tissues with risk of colorectal carcinoma in Pakistan.
Qayyum MA; Farooq T; Baig A; Bokhari TH; Anjum MN; Mahmood MH; Ashraf AR; Muddassir K; Ahmad M
J Trace Elem Med Biol; 2023 Sep; 79():127234. PubMed ID: 37302218
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics, Clinical Outcomes, and prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn's Disease.
Suttichaimongkol T; Loftus EV
Inflamm Bowel Dis; 2024 Apr; 30(4):547-553. PubMed ID: 37279944
[TBL] [Abstract] [Full Text] [Related]
[Next]
